ClinVar Miner

Submissions for variant NM_032043.2(BRIP1):c.797C>T (p.Thr266Met) (rs550031006)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000116165 SCV000150074 uncertain significance not provided 2018-11-12 criteria provided, single submitter clinical testing This variant is denoted BRIP1 c.797C>T at the cDNA level, p.Thr266Met (T266M) at the protein level, and results in the change of a Threonine to a Methionine (ACG>ATG). BRIP1 Thr266Met was observed in a control subject in a breast cancer case-control study, but was not observed in any breast cancer cases (Easton 2016). This variant was observed at an allele frequency of 0.01% (1/10138 alleles) in individuals of Ashkenazi Jewish ancestry in large population cohorts (Lek 2016). BRIP1 Thr266Met is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether BRIP1 Thr266Met is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV000198777 SCV000255180 uncertain significance Familial cancer of breast; Fanconi anemia, complementation group J 2019-12-31 criteria provided, single submitter clinical testing This sequence change replaces threonine with methionine at codon 266 of the BRIP1 protein (p.Thr266Met). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and methionine. This variant is present in population databases (rs550031006, ExAC 0.02%). This variant has not been reported in the literature in individuals with BRIP1-related disease. ClinVar contains an entry for this variant (Variation ID: 128196). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color RCV000448094 SCV000537590 uncertain significance Hereditary cancer-predisposing syndrome 2020-03-23 criteria provided, single submitter clinical testing
Ambry Genetics RCV000448094 SCV000661480 uncertain significance Hereditary cancer-predisposing syndrome 2019-03-11 criteria provided, single submitter clinical testing Insufficient or conflicting evidence
Counsyl RCV000662521 SCV000785075 uncertain significance Fanconi anemia, complementation group J; Neoplasm of ovary 2017-04-05 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000198777 SCV000895114 uncertain significance Familial cancer of breast; Fanconi anemia, complementation group J 2018-10-31 criteria provided, single submitter clinical testing
Leiden Open Variation Database RCV000116165 SCV001364485 uncertain significance not provided 2019-08-13 no assertion criteria provided curation Curator: Arleen D. Auerbach. Submitter to LOVD: Yukihide Momozawa.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.